Kornimate/medical-research-clean huggingface dataset:
human papillomavirus (hpv) types present in external genital warts (egw) in the argentinean population

Conditions: Condylomata Acuminata

Summary: the summary of this study is to know which hpv types are present in genital warts in argentinean population.

this is a prospective study. patients will be evaluated for the presence of external anogenital warts in our clinic. biopsy will be performed if patients have genital lesions consistent with genital warts of the external genitalia or perianal area. all patients will be provided with an informed consent for the excision biopsy procedure, before performing the biopsy of the lesion. biopsy specimens will be held in a formol 10% solution and will be sent to the pathologist. a portion of each sample will be processed for histological analysis, which will be performed by one pathologist. the remainder of each specimen will be saved to extract dna for pcr analysis. all biopsies will be analyzed by the same pathologist who will confirm the histology of the lesion. a part of the specimen will be kept frozen and if the biopsy confirm genital warts by histology; then the specimen will be analyzed by pcr for the presence of dna hpv 6 and 11. the pcr analysis will be done by microarrays. detection is performed in a subtype of array platform system which detects the different types of virus. the reports will be as undetectable / detectable and type. the study will be conducted in the institute of gynecology and fertility (institute affiliated with the school of medicine - university of buenos aires). chronogram of activities: all activities will be done in a maximum of 60 days 1. st visit: detect external genital warts and firm informed consent and take the biopsy 2. nd visit: inform the result

Eligibility criteria:
inclusion criteria: * women between 15 and 45 years old, with external genital warts exclusion criteria: * women taking corticoid therapy, having an immunosuppressed disease, pregnancy, cancer related to hpv, vin confirmed by histology, other sexually transmitted infection, hiv+ known

Keywords: genital warts hpv types sexually transmitted diseases skin diseases, viral tumor virus infections skin diseases, infectious skin diseases papillomavirus infections dna virus infections virus diseases sexually transmitted diseases, viral
endothelial function in a sample group of patients from the icare study

Conditions: Cardiovascular Diseases

Summary: the icare study, clinicaltrials.gov id number: nct00220831 and protocol number kl-2004, is recruiting diabetic patients with haptoglobin phenotype 2-2, which are randomised to either vitamin e 400iu per day or placebo. patients will be followed for 4 years for the major cardiovascular complications of diabetes, acute myocardial infarction (mi), stroke and cardiovascular mortality (see icare protocol). the efi study, endothelial function in icare will recruit a sample group of 50 patients from the icare cohort. these patients will complete all requirements by icare protocol and in addition will be tested for endothelial function by a non-invasive method of flow mediated dilatation (fmd).

fifty patients will be randomly sampled from the icare untreated cohort (registry) of diabetic patients with hp2-2 phenotype which were not randomised to treatment under icare study. patients will be randomised to either vitamin e 400 iu/d or placebo upon sampling for efi study. the patients will be tested for endothelial function by a method of post ischemic flow mediated dilatation. all patients will undergo a baseline endothelial function test and then start taking the study drug for 2 months. at the end of two months of therapy the patients will undergo a second endothelial function test, then therapy will be stopped for 2 weeks and a cross over will be performed for an additional 2 months of therapy which in the end the third and final endothelial function test will be done. an interim results analysis is set to be done once the first 20 patients completed the protocol. in case of significant differences between the groups, study principal investigators will decide about study completion.

Eligibility criteria:
inclusion criteria: * diabetic patients aged 55 and above exclusion criteria: * patient who takes antioxidant treatment will be asked to stop, or cannot be included in the study. * patients who had a cardiovascular disease (cvd) incident (myocardial infarction \[mi\], stroke, transient ischemic attack \[tia\]), unstable angina pectoris, uncontrolled hypertension (htn), will have to wait a month after stabilization to be included in the study. * allergy to vitamin e.

Keywords: diabetes endothelial function haptoglobin
prolonged exposure therapy to treat posttraumatic stress disorder in pregnant patients receiving medications for opioid use disorder

Conditions: Posttraumatic Stress Disorder; Opioid Use Disorder; Pregnancy

Summary: the goal of this clinical trial is to learn if a treatment for adults with ptsd called prolonged exposure + incentives (pe+) works to treat pregnant patients who are already receiving treatment for opioid use disorder. the main question it aims to answer is: does pe+ decrease ptsd symptoms? all participants will receive pe+ to see if their ptsd symptoms at the end of the trial are less than at the beginning. participants will: * receive individual pe+ therapy for 1 hour weekly for 12 weeks. * receive financial incentives for attending each pe+ session. * attend assessment visits every 4 weeks for the 12 weeks of the trial. * allow research staff to collect some information about their labor and delivery from their medical records after their babies are born.


Eligibility criteria:
inclusion criteria: * female * \>18 years old * gestational age ≤ 25 weeks * maintained on a stable methadone or buprenorphine dose for \>14 days prior to the study * meet current dsm-5 posttraumatic stress disorder criteria based on the clinician administered ptsd scale for dsm-5 * participants receiving psychotropic medications must be maintained on a stable dose for \>14 days prior to enrollment. exclusion criteria: * male * under 18 years old * gestational age \> 25 weeks * not receiving medication for opioid use disorder * no current diagnosis of ptsd * current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the mini international neuropsychiatric interview * enrolled in another ongoing evidence-based treatment for ptsd.
thrombolysis with intra-arterial urokinase

Conditions: Arterial Occlusion Mesenteric Artery Superior

Summary: patients with acute superior mesenteric artery (sma) occlusion were included in this study. the clinical presentation and effect of the recanalization of the sma was analyzed on follow-up angiography.

thirteen patients with acute sma occlusion who underwent intra-arterial urokinase thrombolysis between 2008 and 2020 were retrospectively evaluated. clinically, the abdominal pain and the effect of the sma on angiography will be compared in response and non-response groups.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of sma occlusion exclusion criteria: * shock in the triage screening * peritonitis * 3. intramural gas, mesenteric or portal venous gas on contrast-enhanced abdominal ct

Keywords: intra-arterial urokinase
a safety, tolerability, efficacy, and pharmacokinetics study of hec96719 in subjects with non-cirrhotic non-alcoholic steatohepatitis

Conditions: Non-Alcoholic Steatohepatitis

Summary: this is a phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of hec96719 in non-cirrhotic nash patients.


Eligibility criteria:
inclusion criteria: * an informed consent document must be signed and dated by the subject * male or female, 18 to 65 years of age * body mass index (bmi)≥18.0 and≤35.0 kg/m2, and weight≥40 kg; * presumed nash based on clinical characteristics or prior liver biopsy * mri pdff liver fat content ≥ 10 % exclusion criteria: * previous diagnosis of other forms of chronic liver disease * laboratory screening results: * ast \> 5 x uln * alp \> 3 x uln * total bilirubin \> 1.5 x uln * albumin \< 3.2 g/dl * inr \> 1.3 * platelet count \< 100,000 /mm3 * creatinine clearance \<60 ml/min (based on cockroft gault method) * previous exposure to oca * uncontrolled diabetes mellitus * presence of cirrhosis * patients with contraindications to mri imaging
sex difference in preemptive analgesic effects with flurbiprofen axetil on postoperative pain and sleep quality

Conditions: Preemptive Analgesia; Sex Difference; Flurbiprofen Axetil; Postoperative Pain; Postoperative Sleep Quality

Summary: in humans and animals, circadian rhythm sleep cycle plays an important role on maintaining and regulating basic physiological homeostasis, such as cognitive function, glucose metabolism, memory consolidation, immune function and growth hormone secretion. the induction of general anesthesia leads to a state of reduced responsiveness, which is often described by anesthesiologists and patients as "sleep". this seems to be a common problem in the case of patients under general anesthesia, besides surgery trauma and general anesthetics may change sleep function and sleep cycle perioperatively, the postoperative complications such as pain, nausea and vomiting etc after general anesthesia may also reduce postoperative sleep quality.flurbiprofen axetil is a new non-steroidal anti infection analgesic(nsaids), which is widely used for analgesia to reduce the dose of opioids and the occurrence of adverse reactions, such as declined sleep quality, respiratory depression, nausea and vomiting . preemptive analgesia is an analgesic intervention that begins before surgery to prevent the nervous system from becoming sensitive to subsequent stimuli that may aggravate pain. a large number of experimental studies have shown that use flurbiprofen axetil preoperatively is better than use it postoperatively. however, limited information was reported before on the effect of factors such as age, gender, preoperative negative mood such as anxiety and depression, type and length of surgery, which could influence postoperative pain and analgesic consumption and the association between postoperative sleep quality and postoperative pain intensity. at present, there has been less previous evidence for how preemptive analgesic with flurbiprofen axetil affect postoperative sleep quality through its effect on postoperative pain of patients with different sex under general anesthesia.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 80 years; 2. american society of anaesthesiologists (asa) physical status i-ⅲ. exclusion criteria: 1. patients with central nervous system and mental illness; 2. patients with preoperative sleep disorders; 3. patients with a history of sedation, analgesia or antidepressants; 4. patients with sleep apnea or obstructive sleep apnea hypopnea syndrome; 5. patients with chronic gastritis and gastric ulcer 6. patients who are allergic to flurbiprofen axetil.
a clinical trial to evaluate the preference regarding convenience of medication and efficacy/safety of sugamet®xr tablet 5/1000mg

Conditions: Diabetes Mellitus, Type 2; Renal Disease; Diabetes Mellitus; Metabolic Disease; Endocrine System Diseases

Summary: multi-center, open-label, single arm study to evaluate the preference regarding convenience of medication, efficacy and safety of sugamet xr tab. 5/1000mg in patients with type 2 diabetes and renal diseases


Eligibility criteria:
inclusion criteria: * aged ≥60 years * subjects with type 2 diabetes mellitus * subjects treated with dpp-4 inhibitor and 1,000mg/day dose of metformin 1t/qd for at least 8 weeks prior to screening * subjects with hba1c≤7.5% at screening * subjects with 45ml/min/1.73m2≤egfr≤90ml/min/1.73m2 at screening * subjects with fasting glucose≤200 at screening * subjects with 18.5kg/m2≤bmi≤40kg/m2 at screening exclusion criteria: * patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus * esrd or patients who have kidney dialysis * subjects with alt and ast 3 times or higher than upper normal range
a study to assess the safety and effect of tc-5214 in patients with major depressive disorder.

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to assess the safety and effect of tc-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.


Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent before initiation of any study-related procedures. * the patient must have a clinical diagnosis of major depressive disorder (mdd) with inadequate response to no more than one antidepressant. * women of child-bearing potential must have a negative urine pregnancy test and confirmed use of a highly effective form of birth control before enrollment and until 3 months after their last dose of study drug. * outpatient status at enrollment and randomization. exclusion criteria: * patients with a lifetime history of bipolar disorder; psychotic disorder or post-traumatic stress disorder. * patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide. * patients with any significant unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic, neurologic, or any other medical conditions that might confound the study or put the patient at greater risk during study participation. * history of stroke or transient ischemic attack, seizures or seizure disorder, head trauma including closed head injury. * pregnancy or lactation.

Keywords: major depressive disorder mdd monotherapy inadequate response to antidepressant therapy
cancer control following polypectomy

Conditions: Colon Cancer

Summary: this study evaluates strategies for the surveillance of post-polypectomy patients for the control of bladder cancer


Eligibility criteria:
inclusion criteria: * referral for colonoscopy or * referral for proctoscopy or for a complete colonoscopy after a proctoscopy or flexible sigmoidoscopy exclusion criteria: * prior history of colon cancer, unrelated polypectomy, inflammatory bowel disease, family history of familial polyposis

Keywords: large bowel cancer polyps colorectal cancer
comparison of superomedial and inferior pedicle techniques in mammaplasty

Conditions: Breast Hypertrophy

Summary: the aim of this study is to evaluate superomedial pedicle and inferior pedicle techniques in breast reduction for egyptian females and compare between both pedicles regarding cosmetic outcomes, possible complications, patient satisfaction and time of operation.

the female breast is one of the most attractive aesthetic areas in female anatomy. the size, shape, and symmetry of the breasts can have a dramatic effect on the women's wellbeing. reduction mammaplasty is certainly one of the operations; plastic surgeons can significantly contribute to a woman's quality of life. macromastia or breast hypertrophy is a pathologic condition consisting of hypertrophy of the breast. it generates both physical and psychological distress, presenting a significant threat to a woman's health-related quality of life. regarding physical distress macromastia always associated with a number of musculoskeletal complications, including neck pain, back pain, headache, peripheral neuralgias, and shoulder pain. often, women with mammary hypertrophy experience intertriginous skin maceration and other rashes, as well as infections all the result of heavy, pendulous breasts. in short, a woman's breast size can affect her attitudes, career choices, and personal life in many ways. ideal technique should end in a beautiful breast, which has good size with fullness in the upper part, attractive shape with adequate projection, elegant curves, and a nipple areola complex that is pleasing in shape and position. the result should last over years. the inferior pedicle technique has been described with many variations by surgeons such as ribeiro and robbins with the nipple and areola being carried on a dermal pedicle, and it is probably one of the most popular breast reduction techniques currently in use in the united states. advantages of this are well known. it is a rapid and safe technique that can be used on almost every breast size. it has been shown to be as good as or better than other techniques in the preservation of the neurovascular supply to the nipple. it is easily taught and learned. the superomedial pedicle technique was first described by orlando \& gutherie as a modification of the superior pedicle technique. in this technique the nipple \& areola (nac) is transposed on a superomedial de-epithelialized pedicle which contains a thin layer of subcutaneous tissue to protect the dermal blood supply.

Eligibility criteria:
inclusion criteria: * bilateral breast hypertrophy exclusion criteria: * congenital breast anomalies. * pregnant, lactating or smoker patient. * previous breast reductions. * co-morbid diseases e.g. diabetes , liver cirrhosis or thyroid disorders. * body dysmorphic disorder * patients on long term medications e.g. immunosuppressive drugs, steroids or cytotoxic drugs.

Keywords: breast reduction mammaplasty breast-q patient satisfaction patient reported outcome measures superomedial pedicle inferior pedicle
agitation in alzheimer's disease

Conditions: Alzheimer Disease

Summary: agitation affects 70 to 90 percent of patients with ad. signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. these behaviors often make caring for patients at home very difficult. trazodone and haldol are two of the most commonly prescribed drugs for agitation in ad patients. behavior management, a non drug approach, has been effective in reducing signs of agitation. researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in ad patients and determine which is the best treatment. the alzheimer's disease cooperative study, with funding from the national institute on aging, is conducting an agitation treatment program at 21 sites in 16 states. this study will assess which of the above treatments is most effective.


Eligibility criteria:
inclusion criteria: * memory problem consistent with a probable diagnosis of alzheimer's disease (ad) * agitation symptoms for at least the past 2 weeks * patient has caregiver who can participate * patient lives in the same household as the caregiver

Keywords: alzheimer's disease psychomotor agitation behavioral symptoms haloperidol trazodone anti-psychotic agents anti-depressant agents
acute sore throat pain study

Conditions: Acute Sore Throat Pain

Summary: "sore throat is one of the most common complaints encountered in clinical practice. and in 65% of cases, the infection is thought to be viral in nature. the aim of this study is to evaluate the analgesic profile of 3 ibuprofen lozenges after single administration in acute sore throat pain."


Eligibility criteria:
inclusion criteria: * male or female patients 18 years and older * patients with a sore throat associated or not with an upper respiratory tract infection ≥ 24 hours and ≤ 5 days duration, in the absence of streptococcus group a exclusion criteria: * patients with hypersensitivity to ibuprofen or other nsaids or the excipients. * patients having used analgesics or antiseptics or any topical throat treatment or any local medication containing a local oral anaesthetic within 6 hours before study entry and who use analgesics more than ≥ 3 times per week. * patients having used any anti inflammatory treatment or any long-acting or slow release analgesics within 12 hours before study entry * patients having taken antibiotics within 14 days before study entry.

Keywords: sore throat pain tonsillopharyngitis upper respiratory tract infection
safety and efficacy of the use of tissue plasminogen activator (tpa) in intra-abdominal collections in children - a prospective study

Conditions: Intra-abdominal Abscess

Summary: the objective of this study is to establish the efficacy of tpa when used in pediatric intra-abdominal abscesses immediately after percutaneous drainage, irrespective of the ultrasound appearance or consistency of the drained fluid.

the use of tpa in pediatric abdominal abscesses is poorly defined. the indications are somewhat subjective and the dosage guidelines vary between institutions. some studies have suggested that it be administered at, or soon after, the time of drainage if the ultrasound appearance of the collection is complex and/or septated, or if the initial aspirated contents are thick and viscous. both criteria are difficult to accurately define and implement. in many instances, when there is minimal ongoing drainage despite follow-up ultrasound appearances suggesting a significant residual collection, tpa is administered several days following the initial procedure. the purpose of this study is to establish the efficacy of tpa in the initial treatment of all pediatric intra-abdominal abcesses and a standardized manner in which it can be used. this may eventually lead to a change in practice in the management of this patient population.

Eligibility criteria:
inclusion criteria: 1. all patients under the age of 18 years with intra-abdominal bacterial abscesses requiring percutaneous drain insertion (including transrectal drains). 2. drain(s) must be inserted within the 23hrs prior to enrollment in the study. 3. the underlying diagnosis of the condition will not affect the enrollment of the patient unless it is detailed within the exclusion criteria (section 4.1.2). 4. patients and parents must have signed informed consent to participate in the study. exclusion criteria:1. 1. pancreatic abscess (not bacterial in nature) 2. known coagulation impairment 3. known central nervous system tumor or abscesses 4. arteriovenous malformation 5. aneurysm or history of central nervous system bleeding 6. hypersensitivity to tpa 7. recent administration of an investigational drug (within previous 30 days) 8. pregnancy 9. breast-feeding 10. fulminant hepatic failure 11. proven fistula (as it will alter the drainage time) or any abscess secondary to crohn's disease (because fistula existence cannot be excluded) 12. necrotizing enterocolitis 13. children requiring 4 or more drains

Keywords: intra-abdominal abscess tpa alteplase cathflo